182 filings
8-K
ZVRA
Zevra Therapeutics Inc
13 May 24
Submission of Matters to a Vote of Security Holders
4:47pm
8-K
ZVRA
Zevra Therapeutics Inc
8 May 24
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
7:54am
8-K
ZVRA
Zevra Therapeutics Inc
10 Apr 24
Entry into a Material Definitive Agreement
7:46am
8-K
ZVRA
Zevra Therapeutics Inc
28 Mar 24
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
4:35pm
8-K
ZVRA
Zevra Therapeutics Inc
26 Mar 24
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of
8:28pm
8-K
n4av5oo43g
5 Mar 24
Regulation FD Disclosure
7:34am
8-K
zqfmgomeem5v55a1niu
4 Mar 24
Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8:24am
8-K
din4xn5u9eci4uz
28 Feb 24
Amendments to Articles of Incorporation or Bylaws
4:29pm
8-K/A
k602duxftikq17i2i
5 Feb 24
Financial Statements and Exhibits
12:00am
8-K
sqz d0r0a
23 Jan 24
Departure of Directors or Certain Officers
7:37am
8-K
88wsuyd d9
8 Jan 24
Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
8:03am
8-K
ilpiesiewny3v8j
27 Dec 23
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug Administration
7:48am
8-K
86d dv3xomf0yz
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
8-K
u2ggminzelbxy
7 Nov 23
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial
7:25am
8-K
h17 ocgybwg
30 Oct 23
Other Events
8:25am
8-K
zb4f5
10 Oct 23
Departure of Directors or Certain Officers
5:12pm
8-K
gkzh3
31 Aug 23
Other Events
5:25pm
8-K
864r5n7p 6vj
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
wyo8 dgpt9vn8vre58
14 Aug 23
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023
7:48am
8-K
h6hqyma 2xgpplk
7 Aug 23
Departure of Directors or Certain Officers
4:52pm